- Coordinator
- Carmat, France
- Runs
- 1 October 2022 to 30 June 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €11.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190185733
What the project is doing
In the project's own words, from its summary on CORDIS.
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure. Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure.
The device is electro-hydraulically driven with a shape close to that of a human heart. Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body. Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility.
With Aeson®, Carmat is creating a new therapeutic class of “physiologic heart replacement therapy” (PHRT).
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Carmat | Velizy-Villacoublay | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI